• Korean Chemical Engineering Research
• /
• 제56권5호
• /
• pp.711-717
• /
• 2018

상피세포 성장인자(Epidermal Growth Factor, EGF)는 세포 분열을 자극하고 의약적 용도가 다양하다. EGF는 3개의 이황화 결합을 갖고 불용성으로, 대장균에서 고효율 발현에 대한 연구가 잘 이루어지지 않았다. EGF 유전자를 작은 유비퀴틴 관련 유전자(small ubiquitin-related modifier gene, SUMO)와 결합하고 DE3 대장균에서 발현시켰다. IPTG (Isopropyl-${\beta}$-D-Thiogalactopyranoside)로 유도하여 대장균 세포 단백질의 38.9%로 융합단백질이 발현되었고, Ni-NTA 친화성 크로마토그래피로 분리하였다. 그 후 유비퀴틴 분해효소반응으로 융합단백질에서 EGF를 얻은 후 다시 Ni-NTA 크로마토그래피로 분리 하였다. 최종적으로 정제된 EGF의 순도는 HPLC로 분석하였으며, 98%이상의 순도를 얻을 수 있었다.

• Radiation Oncology Journal
• /
• 제24권1호
• /
• pp.67-76
• /
• 2006

목적 : 구내염은 두경부종양이 있는 암환자에게 방사선 및 항암제 치료 시술 시 매우 흔하게 발생하는 합병증이다. 본 연구는 Rat 의 방사선성 구내염 모델에서 recombinant human epidermal growth factor (rhEGF)의 효과를 평가하고자 하였다. 대상 및 방법: 25 Gy의 방사선량으로 두부에 단회 조사한 Rat를 무작위로 7마리씩 무처치군, 부형제 처치군, rhEGF 15 또는 $30{\mu}g/day$ 구강 내 처치군으로 나누었으며, 방사선을 조사하지 않은 7 마리의 Rat를 정상시험군으로 나누었다 rhEGF 시료 및 부형제는 1일 3회 Rat 의 구강점막에 매일 도포하였다. Rat의 생존율, 체중변화 및 사료섭취량을 18일 동안 관찰하였으며, 방사선 조사 후 7 일 및 18 일째에 Rat의 구강점막을 조직학적으로 평가하였다. 결과 : 실험종료 시점에서 rhEGF 15 또는 $30{\mu}g/day$ 구강 내 처치군이 모두 33%의 생존율을 보인 것에 비하여, 무처치군 및 부형제 처치군은 모두 0%의 생존율을 보였다. 체중변화에서도 rhEGF 처치군은 방사선 조사 후 2일부터 7일까지 부형제 처치군에 비하여 Rat 의 평균체중이 통계적으로 더욱 무거웠다 사료섭취율은 모든 시험군에서 방사선 조사 후 4 일까지 감소하는 양상을 보이다가, rhEGF 15 또는 $30{\mu}g/day$ 구강 내 처치군에서 14일째에 뚜렷한 사료섭취율의 증가가 관찰되었다. 방사선 조사 후 7 일째의 조직학적 분석 결과, rhEGF 15 또는 $30{\mu}g/day$ 구강 내 처치군의 Rat 에서는 점막 표피층의 각질세포의 종창 및 변성만이 관찰되었던 것에 비하여, 무처치군 및 부형제 처치군에서는 심한 위막성 또는 궤양성 구내염이 관찰되었다. 결론; rhEGF (15 또는 $30{\mu}g/day$ 구강 내 처치군) 처치에서 방사선 조사로 유발시킨 Rat의 구내염 모델에서 유의성 있는 치유 효과를 확인하였으며, 본 시험결과로 rhEGF가 방사선에 의해 유발된 구내염을 치료할 수 있는 임상 제제로써의 가능성을 볼 수 있었다.

• 한국산학기술학회논문지
• /
• 제22권6호
• /
• pp.542-549
• /
• 2021

본 연구의 목적은 재조합 인간 상피세포 성장인자(hEGF)의 발현 확인 및 정제의 용이성을 위해 단백질의 N-말단에 융합된 부분을 제거하기위하여 기존의 고가의 효소를 사용하지 않고 간단한 화학처리로 융합 태그를 절단하면서도 여전히 친화성 크로마토그래피로 정제가 가능한 재조합 hEGF의 경제적이며 공정이 단순화된 제조법을 제공하는 것이다. 인간 상피세포 성장 인자는 인간 세포 성장 및 증식에 매우 중요한 호르몬이며 이 단백질에 대한 발현 및 정제에 관한 많은 연구가 보고 되었다. 본 연구에서는 hEGF 유전자를 대장균 코돈에 최적화 하였으며 N-말단에 Hydroxylamine에 의한 절단이 가능한 Asparagine과 Glycine이 발현되도록 포함하여 설계하였다. 제조한 DNA를 대장균 발현 벡터인 pRSET_A에 삽입하여 발현용 균주 BL21 (DE3)에 형질전환 시켰으며 재조합 융합 단백질은 대장균에서 샤페론 벡터 pG-Tf2와 성공적으로 공발현 되었다. 발현된 융합 단백질은 Ni-NTA 컬럼 크로마토그래피로 정제한 후 Hydroxylamine으로 처리해 N-말단 융합부분을 제거하였으며 SDS-PAGE를 통해 확인하였다. ELISA 분석 결과 재조합 EGF의 활성이 상업용 hEGF와 92% 이상 유사한 것으로 나타났으며 피부 섬유아세포의 세포증식을 촉진하는 것으로 확인 되었다.

• 한국미생물·생명공학회지
• /
• 제24권5호
• /
• pp.553-559
• /
• 1996

We have designed nucleotide sequences of hEGF structural gene to eliminate the N-terminal methionine residue incorporated during the translation initiation step, and constructed recombinant human epidermal growth factor (rhEGF) secretion plasmids pYHB101, and pYHB2 in which pelB signal sequence-hEGF gene was expressed under the control of the T7, and tac promoter, respectively. We also constructed pYHB1 vector which contains rhEGF gene controlled by T7 promoter. The transformant with pYHB101 showed relatively slow growth pattern compared to the transformant with pYHB1. However, we observed that the transformant with pYHB101 secreted rhEGF of 13 mg/l significantly after 5 hr induction with 1 mM IPTG and that the T7 promoter was more effective than tac promoter when connected to pelB signal sequence. The amount of rhEGF was 14 mg/l under the sub-optimized condition.

• Biomolecules & Therapeutics
• /
• 제7권1호
• /
• pp.7-13
• /
• 1999

The stimulatory effect of recombinant human basic fibroblast growth factor (bFGF) on wound healing was evaluated in healing-impaired animal models. Full-thickness wounds were made in prednisolone-treated mice, streptozotocin (STZ)-induced diabetic rats and mitomycin C (MMC)-treated rats. Saline or bFGF at a dose of 1, 5, or $25\mu\textrm{g}$ per wound was applied to the open wound once a day for three to five days. The degree of wound healing was assessed using wound size and histological parameters such as degree of epidermal and dermal regeneration. Local application of bFGF accelerated wound closure significantly in a dose-dependent manner in all healing-impaired wounds (p<0.05). The wound healing effect of bFGF was further confirmed by histological examination in MMC-treated rats. Epidermal and dermal regeneration were enhanced in bFGF-treated wounds with a dose-related response. Dermal regeneration parameters such as collagen matrix formation and angiogenesis were significantly increased in $5\mu\textrm{g}$, or $\25mu\textrm{g}$ of bFGF-treated wounds when compared to saline-treated wounds (p<0.05). pectin immunostaining on day 8 for vascular endothelium showed an increased number of neovessels in bFGF-treated wounds. These results suggest that topical application of bFGF has beneficial effects on wound healing by angiogenesis and granulation tissue formation in healing-impaired wounds.

• 약학회지
• /
• 제41권3호
• /
• pp.328-334
• /
• 1997

Pharmacokinetics of DWP401, a recombinant human epidermal growth factor (rhEGF), was studied using radioimmunoassay (RIA) and $^{125}I$-DWP401 in rats. When DWP401 was adm inistered i.v. at doses of 50 and 500 mcg/kg, the plasma DWP401 disappeared biiexponentially with terminal half life of 4.7 and 92.8 min. The $C_{max}$ and $T_{max}$ after s.c. administration of ti at doses of 50 and 500 ${\mu}g$/kg were determined to be 23.6 and 17.5 ng/ml at 50 ${\mu}g$/kg, and 261.4 ng/ml and 36.8 min, respectively. Both the total urinary and biliary recoveries of intact DWP401 2343 very low (<0.4%), probably due to its extensive degradation in the body. the concentration ratio of DWP401 between the organ and plasma decreased especially in the liver and kidney as the dose and time after the dose increased. For example, the liver/plasma and kidney/plasma concentration ratio of DWP401 at 2.5 min after i.v. doses of 50 ${\mu}g$/kg were comparable and much larger than unity. But, the ratio at 2.5 min after i.v. doses of 500${\mu}g$/kg was much larger in the kidney that in than in the liver. These results suggest that the systemic administration of DWP401 might be subject to rapid and extensive clearance from circulation within several hour after main distrbution to liver and kidney.

• 한국미생물·생명공학회지
• /
• 제26권1호
• /
• pp.61-67
• /
• 1998

재조합 인간상피세포 성장인자(rhEGF)가 E. coli BL21(pYHB101) 균주를 사용하여 발현되었다. 10g/L glucose를 첨가한 변형된 MBL 배지를 사용하여 10 $\mu\textrm{m}$ IPTG/lactose로 2시간 동안 유도배양한 후 27$^{\circ}C$에서 48시간 동안 배양하였을 때 44.5 mg/L의 rhEGF가 발현되었다. 상기의 결과는 E. coli BL2l(pYHB101)를 사용하여 rhEGF를 발현시 lactose를 IPTG와 동일한 유도 물질로 사용 가능하다는 것을 시사하는 것이다. 회분식 배양에서 glucose를 10 g/L 첨가한 변형된 MBL 배지에 유도물질로 10 $\mu\textrm{m}$ lactose를 사용하였으며 28시간 동안 배양하였을 때 최대 45 mg/L의 rhEGF가 발현되었다. 유가식 배양에서 정지기에 0.5%(w/v) lactose와 0.25%(w/v) yeast extract를 첨가하였을 때 160mg/L의 rhEGF가 발현되었으며 94.3%가 분비되었다. 이에 비하여 유도기에 lactose를 첨가한 경우는 120 mg/L의 rhEGF가 발현되었으며 cytoplasm으로 발현된 불용성 봉입체의 비율은 20.9%에 달하였다. 이것은 lactose의 첨가시기가 E. coli BL2l(pYHB101)로부터 soluble rhEGF의 생성에 중요하다는 것을 확인한 결과이다.

• 약학회지
• /
• 제45권2호
• /
• pp.190-204
• /
• 2001

This study was conducted to investigate for its effects on reproductive and developmental toxicity of recombinant human epidermal growth factor (rhEGF) in Sprague-Dawley rats. Male rats were administered rhEGF at doses of 1, 10, 100, and 1000$\mu$g/kg/day, respective1y, by subcutaneous injection from 63 days before and throughout to mating period until the day before sacrifice. Female rats were administered rhEGF at the same doses from 14 days before mating to day 20 of gestation or to day 21 of lactation. We examined the male and female fertility indices and maternal toxicity of F0 parental animals. Also, we examined the external, visceral, or skeletal malformation of fetuses, growth and development, behavior, and/or reproductive performance of F1 animals. At the highest dose (1,000 $\mu$g/kg), the mean body weights of F0 animals were significantly increased in males and females at 3 or 2 weeks after treatment, respective1y. No clinical signs and food intakes were observed at any time during the experimental period by rhEGF treatment. In autopsy examination, the relative and absolute liver weights significantly increased in both sexes of 1,000 $\mu$g/kg. At the highest dose (1,000 $\mu$g/kg), there was a statistically significant increase of pregnancy period and the number of dead fetuses. Moreover, significant increase of mean fetal body weight and decrease of number of live fetuses, which related to the difficult dilivery were observed in highest dose group. In Fl examination, no adverse effects on external, visceral, and skeletal malformation, physical and functional development, behavior or reproductive ability of Fl animals were observed in any group. Also, there was no significant difference between control and treated groups in copulation or fertility indices of Fl animals. These results indicate that rhEGF had no adverse effect on fertility and reproductive ability of Sprague-Dawley rats.

• Archives of Pharmacal Research
• /
• 제28권8호
• /
• pp.988-994
• /
• 2005

The purpose of the present study was to prepare multivesicular liposomes with a high drug loading capacity and to investigate its potential applicability in the oral delivery of a peptide, human epidermal growth factor (rhEGF). The multivesicular liposomes containing rhEGF was prepared by a two-step water-in-oil-in-water double emulsification process. The loading efficiency was increased as rhEGF concentration increased from 1 to 5mg/mL, reaching approximately $60\%$ at 5 mg/mL. Approximately $47\%$ and $35\%$ of rhEGF was released from the multivesicular liposomes within 6 h in simulated intra-gastric fluid (pH 1.2) and intra-intestinal fluid (pH 7.4), respectively. rhEGF-loaded multivesicular liposomes markedly suppressed the enzymatic degradation of the peptide in an incubation with the Caco-2 cell homogenate. However, the transport of rhEGF from the multivesicular liposomes to the basolateral side of Caco­2 cells was two times lower than that of the rhEGF in aqueous solution. The gastric ulcer healing effect of rhEGF-loaded multivesicular liposomes was significantly enhanced compared with that of rhEGF in aqueous solution; the healing effect of the liposomes was comparable to that of the cimetidine in rats. Collectively, these results indicate that rhEGF-loaded multivesicular liposomes may be used as a new strategy for the development of an oral delivery system in the treatment of peptic ulcer diseases.

• 대한약학회:학술대회논문집
• /
• 대한약학회 2001년도 Proceedings of the Pharmaceutical Society of Korea
• /
• pp.234.3-235
• /
• 2001